[
  {
    "ts": null,
    "headline": "FDA Approves New DexCom Diabetes Device",
    "summary": "The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system.",
    "url": "https://finnhub.io/api/news?id=a4f1fe7766d7f826d16900557c070b67f75007774862e57868b964313f5b4819",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744306621,
      "headline": "FDA Approves New DexCom Diabetes Device",
      "id": 133873443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system.",
      "url": "https://finnhub.io/api/news?id=a4f1fe7766d7f826d16900557c070b67f75007774862e57868b964313f5b4819"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch",
    "summary": "The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute Relative Difference (MARD) of 8.0%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range. Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry New with Dexcom G7 15 Day Longe",
    "url": "https://finnhub.io/api/news?id=b21ef1ec4782e7c2dfb50c7e23d55d0ea063f3802fdd365ea54bcfd3bbd886f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744306102,
      "headline": "FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch",
      "id": 133873444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute Relative Difference (MARD) of 8.0%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range. Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry New with Dexcom G7 15 Day Longe",
      "url": "https://finnhub.io/api/news?id=b21ef1ec4782e7c2dfb50c7e23d55d0ea063f3802fdd365ea54bcfd3bbd886f8"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance",
    "summary": "DexCom  stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food and Drug Administration for a new glucose monitoring system.  Shares of the medical device manufacturer, which specializes in systems for diabetes patients, climbed 2.9% on Thursday.  The gains came after  DexCom  said its G7 15 Day system had been cleared for use in the U.S. for people age 18 years and older.",
    "url": "https://finnhub.io/api/news?id=5fa5a940b7bceabe3e74436e115fd61f972dc0605b0034e5d8b90e5101c613fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744299240,
      "headline": "DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance",
      "id": 133853657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom  stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food and Drug Administration for a new glucose monitoring system.  Shares of the medical device manufacturer, which specializes in systems for diabetes patients, climbed 2.9% on Thursday.  The gains came after  DexCom  said its G7 15 Day system had been cleared for use in the U.S. for people age 18 years and older.",
      "url": "https://finnhub.io/api/news?id=5fa5a940b7bceabe3e74436e115fd61f972dc0605b0034e5d8b90e5101c613fb"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks to Buy in the Tariff-Fueled Market Correction",
    "summary": "For those who can afford it without blowing their budget, it's actually a great idea to pick up shares of top companies on the dip during a correction.  With that in mind, here are two excellent growth-oriented companies to buy in the ongoing market meltdown: tech giant Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) and medical device maker DexCom (NASDAQ: DXCM).",
    "url": "https://finnhub.io/api/news?id=5758b29ab168a38577edb4c643aa9df14a2dff74714d2a3ed10e130164ac634e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744294500,
      "headline": "2 Growth Stocks to Buy in the Tariff-Fueled Market Correction",
      "id": 133843847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "For those who can afford it without blowing their budget, it's actually a great idea to pick up shares of top companies on the dip during a correction.  With that in mind, here are two excellent growth-oriented companies to buy in the ongoing market meltdown: tech giant Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) and medical device maker DexCom (NASDAQ: DXCM).",
      "url": "https://finnhub.io/api/news?id=5758b29ab168a38577edb4c643aa9df14a2dff74714d2a3ed10e130164ac634e"
    }
  },
  {
    "ts": null,
    "headline": "Dexcom nets FDA clearance for 15-day CGM",
    "summary": "The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.",
    "url": "https://finnhub.io/api/news?id=1162191fd5d694f0b0066f177b9f1a4c2c22cb0cacfe3b272fced46fe802fadb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744294041,
      "headline": "Dexcom nets FDA clearance for 15-day CGM",
      "id": 133873445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.",
      "url": "https://finnhub.io/api/news?id=1162191fd5d694f0b0066f177b9f1a4c2c22cb0cacfe3b272fced46fe802fadb"
    }
  },
  {
    "ts": null,
    "headline": "Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device",
    "summary": "Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day period.",
    "url": "https://finnhub.io/api/news?id=5a0e7c0744b919a7585622b21a8490f941a1fb65f97db4baba7ccb35975c33fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744292048,
      "headline": "Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device",
      "id": 133844199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day period.",
      "url": "https://finnhub.io/api/news?id=5a0e7c0744b919a7585622b21a8490f941a1fb65f97db4baba7ccb35975c33fc"
    }
  },
  {
    "ts": null,
    "headline": "Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System",
    "summary": "SAN DIEGO, April 10, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range.4-8",
    "url": "https://finnhub.io/api/news?id=0cceaa6718facf75456b9d1e8f9373c9fea193ef6d71eccca134064b1122ac8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744288200,
      "headline": "Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System",
      "id": 133845248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "SAN DIEGO, April 10, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0%,3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range.4-8",
      "url": "https://finnhub.io/api/news?id=0cceaa6718facf75456b9d1e8f9373c9fea193ef6d71eccca134064b1122ac8d"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System",
    "summary": "DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System",
    "url": "https://finnhub.io/api/news?id=0b0021f636c38990940d432189979aeaf8fe98c1af38dd44c696d9c4d1bd676e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744276380,
      "headline": "DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System",
      "id": 133861220,
      "image": "",
      "related": "DXCM",
      "source": "MarketWatch",
      "summary": "DexCom Shares Rise in Premarket on FDA Clearance for Glucose Monitoring System",
      "url": "https://finnhub.io/api/news?id=0b0021f636c38990940d432189979aeaf8fe98c1af38dd44c696d9c4d1bd676e"
    }
  }
]